Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy

Area of Science:

• Biochemistry
• Genetics
• Molecular Biology

Background:

• X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative disease caused by impaired very long-chain fatty acid (VLCFA) metabolism due to ABCD1 gene mutations.
• Current treatments for X-ALD offer limited clinical benefit, highlighting the need for novel therapeutic strategies.
• Lovastatin, a cholesterol-lowering drug, has shown potential in normalizing VLCFA levels in X-ALD patients.

Purpose of the Study:

• To elucidate the molecular mechanism by which cholesterol lowering reduces VLCFA accumulation in X-ALD.
• To investigate the role of ABCD2 gene expression in response to sterol depletion.
• To establish a link between cholesterol metabolism regulation and peroxisomal fatty acid metabolism.

Main Methods:

• Real-time PCR to assess ABCD2 gene expression in human fibroblasts and monocytes upon sterol depletion.
• Reporter gene assays, site-directed mutagenesis, and gel shift assays to identify regulatory elements in the ABCD2 promoter.
• Analysis of sterol regulatory element-binding protein (SREBP) activation.

Main Results:

• Sterol depletion induces ABCD2 gene expression in human cells via SREBP activation.
• A functional sterol regulatory element was identified in the ABCD2 promoter region.
• Increased ABCD2 expression significantly reduced VLCFA accumulation in X-ALD fibroblasts.

Conclusions:

• Cholesterol lowering activates SREBPs, leading to increased ABCD2 expression.
• This mechanism provides a novel therapeutic approach for X-ALD by linking cholesterol and fatty acid metabolism.
• Targeting SREBP-mediated ABCD2 induction may offer a viable strategy for managing X-ALD.